TLR4 and bacterial infectious disease: To address this question, we pretreated PBMCs with increasing concentrations of EPs 7630 (0.1–3 μg/ml) for 24 h followed by stimulation with TLR3 or TLR4 ligands (mimicking viral or bacterial infection, respectively) for another 24 h.